Assignee: COR Therapeutics, Inc.

Location: SouthSanFrancisco, CA
No. of patents: 74

Browse patents
Browse applications

Number	Title	Issue Date
6376515	Benzamides and related inhibitors of factor Xa Novel benzamide compounds including their pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also described. The comp...	04/23/2002
6369080	Selective factor Xa inhibitors Novel compounds of formula I: ##STR1## including its pharmaceutically acceptable isomers, salts, hydrates, solvates and prodrug derivatives having activity against mammalian factor Xa are described. Compositions containing such compounds are also des...	04/09/2002
6333321	Selective factor Xa inhibitors Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	12/25/2001
6291469	Spiro compounds as inhibitors of fibrinogen-dependent platelet aggregation This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, as shown by formula (I): ##STR1## wherein Q, L, Ai, Bj, R0, R3, R10, m, n, p and q are as ...	09/18/2001
6262047	Selective factor Xa inhibitors Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	07/17/2001
6245743	Inhibitors of factor Xa Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	06/12/2001
6211154	Ketoheterocyclic inhibitors of factor Xa Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	04/03/2001
6211183	Selective factor Xa inhibitors Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	04/03/2001
6210913	Modulation of integrin-mediated signal transduction The present invention discloses that phosphorylation of cytoplasmic tyrosine residues in the ଲ-subunit of integrins is needed for signal protein association. The invention provides methods of identifying signaling partners involved in integrin media...	04/03/2001
6197541	Recombinant thrombin receptors and assays using them The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the ...	03/06/2001
6197748	Ketoheterocyclic inhibitors of factor Xa Ketoheterocyclic compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are usefull in vitro or in vivo for preventing or treating coagulation disorders....	03/06/2001
6124101	Recombinant thrombin receptor and related pharmaceuticals The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the ...	09/26/2000
6117836	Glycosylation-mediated inhibition of factor X Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an 댒-6 linkage are able to inhibit the conversion of human Factor X to hu...	09/12/2000
6069130	Ketoheterocyclic inhibitors of factor Xa Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	05/30/2000
6063794	Selective factor Xa inhibitors Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	05/16/2000
6060588	Bap-1 proteins The present invention provides the amino acid and nucleotide sequence of a protein that binds to 댣 integrins, ଱IIb and Src kinase and is involved in integrin mediated signaling. Based on this disclosure, the present invention provides methods...	05/09/2000
6046169	Inhibitors of factor XA Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	04/04/2000
6043212	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyt...	03/28/2000
6024936	Antibody-based method of localizing activated thrombin receptors The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the ...	02/15/2000
6022861	Ketoheterocyclic inhibitors of factor Xa Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	02/08/2000
5990079	Agents affecting thrombosis and hemostasis Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are...	11/23/1999
5968902	Platelet aggregation inhibitors The isolated and purified PAI from several active snake venoms is described and characterized. In addition, PAIs lacking the Arg-Gly-Asp (RGD) adhesion sequence but containing K* -(G/Sar)-D wherein K* is a modified lysyl residue of the formula R1	10/19/1999
5968897	Agents affecting thrombosis and hemostasis Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are...	10/19/1999
5958732	Platelet aggregation inhibitors An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samp...	09/28/1999
5935926	Platelet aggregation inhibitors An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samp...	08/10/1999
5919765	Inhibitors of factor XA Novel compounds, their salts and compositions related thereto having activity against mammalian factor Xa are disclosed. The compounds are useful in vitro or in vivo for preventing or treating coagulation disorders....	07/06/1999
5916908	Pharmaceutical pyrazole compositions useful as inhibitors of protein kinases A method for selectively inhibiting a kinase is disclosed, which comprises contacting a composition containing a kinase with a compound of the formula: ##STR1## wherein: R1 is lower alkyl, lower hydrocarbyl, aryl lower alkyl, heteroar...	06/29/1999
5874400	Recombinant C140 receptor, its agonists and antagonists, and nucleic acids encoding the receptor Nucleic acid molecules encoding the C140 cell surface receptor have been cloned and sequenced. The availability of C140 receptor DNA permits the recombinant production of the C140 receptor which can be produced on the surface of a cell, including an oocyt...	02/23/1999
5871963	P2u2 purinergic receptor and nucleic acid encoding the receptor A novel subtype of the P2 -purinergic receptor, referred to as the P2U2 receptor, is disclosed. This receptor is activated by four of its agonists in the following order of specificity: UTP>UDP>ADP>ATP. Nucleic acids encoding the rec...	02/16/1999
5872218	Human platelet-derived growth factor receptor extracellular domain antibodies This invention provides antibodies that bind to epitopes of human platelet-derived growth factor receptor (hPDGF-R) fragments, wherein the fragments comprise one or more platelet-derived growth factor (PDGF) ligand binding regions from extracellular domai...	02/16/1999
5866681	Thrombin receptor antagonists Peptide derivatives serving as thrombin receptor antagonists are disclosed, which bear specificity for the cellular thrombin receptor without interfering with the catalytic activities of thrombin. The derivatives generally have the formula ##STR1## ...	02/02/1999
5856448	Antibodies specifically reactive with thrombin receptor and its components The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the ...	01/05/1999
5851839	Platelet aggregation inhibitors Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds....	12/22/1998
5837679	Agents affecting thrombosis and hemostasis Analogs of blood factors which are transiently inactive are useful in treatment of diseases characterized by thrombosis. In addition, modified forms of activated blood factors that generate the active blood factor in serum but have extended half-lives are...	11/17/1998
5817310	Inhibitory immunoglobulin polypeptides to human PDGF beta receptor The present invention is directed towards immunoglobulin polypeptides that specifically bind to the extracellular domain of the human type beta PDGF receptor. The binding of the immunoglobulin polypeptides to the receptor inhibits PDGF-induced (or stimula...	10/06/1998
5807828	Platelet aggregation inhibitors Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds....	09/15/1998
5807825	Platelet aggregation inhibitors An assay for screening snake venom for the presence or absence of platelet aggregation inhibitors (PAIs) based on specific receptor binding is described. Using this assay, the identification and characterization of PAIs in a wide range of snake venom samp...	09/15/1998
5798332	Glycosylation-mediated inhibition of factor X Reagents that specifically bind a carbohydrate target wherein sialic acid is linked at the nonreducing terminus of a glycoside to a galactose or galactosamine residue through an 댒-6 linkage are able to inhibit the conversion of human Factor X to hu...	08/25/1998
5795863	Recombinant agents affecting thrombosis Analogs of Factor Xa (Factor Xai) which are inactive as proteases in the prothrombinase reaction are useful in treatment of diseases characterized by thrombosis. These antithrombotic agents can be conveniently prepared using recombinant techniques....	08/18/1998
5795867	Platelet aggregation inhibitors Peptides useful in inhibiting platelet aggregation are disclosed. These peptides contain the binding sequence Har-G-D and are disulfide-bridged cyclic compounds....	08/18/1998

«First «Previous1 2 Next»Last»

PatentStorm

Quotables

PatentStorm News

Assignee: COR Therapeutics, Inc.